用于口服应用的Pregabalin凝细胞毒性的表征和评估
Gabriela Monteiro Barbosa Xavier1, Lindalva Maria de Meneses Costa Ferreira2, Marcele Fonseca Passos3
1School of Dentistry, Federal University of Pará, Belém 66075-110, PA, Brazil.
Pharmaceuticals (Basel, Switzerland)
|September 28, 2024
概括
治疗口腔疼痛的新局部普雷加巴林 (PG) 凝显示出有希望的结果. 这些凝是稳定的,对人类牙纤维细胞无毒,可能为口腔粘膜疾病提供新的治疗选择.
科学领域:
- 制药科学 制药科学
- 生物材料科学 生物材料科学
- 口腔医学是指口腔医学.
背景情况:
- 普雷加巴林 (PG) 是有效的疼痛管理.
- 需要新的药物输送系统来提高PG疗效和患者的遵守性.
- 局部口服配方提供局部药物输送,可能减少全身副作用.
研究的目的:
- 为准备和描述用于局部口服应用的普雷加巴林 (PG) 碳聚凝.
- 为了评估这些PG凝对人类牙纤维细胞的细胞毒性.
- 评估开发的口腔凝的稳定性和风湿性质.
主要方法:
- 不同度的普雷加巴林溶液被加入到1.0%的碳聚凝基中.
- 进行了热分析 (TG,DSC),FTIR,稳定性和风湿学研究.
- 使用人类牙纤维细胞体 (WG,PG2G,PG5G,PG10G组) 评估了细胞毒性.
主要成果:
- 成功制备了具有pH值6的透明,均的凝.
- 在初步和加速条件下,碳聚凝表现出良好的稳定性.
- 在所有测试的普雷加巴林凝度中,在人类牙纤维细胞中没有观察到细胞毒性.
结论:
- 开发的普雷加巴林凝具有有利的物理化学和稳定性特征.
- 这些配方在体外对人类牙纤维细胞无毒.
- 局部布雷加巴林凝代表了口腔粘膜疼痛管理的有前途的治疗替代方案.
相关概念视频
Antiepileptic Drugs: Potassium Channel Activators
149
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
149
Antiepileptic Drugs: GABAergic Pathway Potentiators
341
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
341
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
266
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
266
Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.2K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.2K


